Skip to main content
. 2016 Mar 23;23(4):692–700. doi: 10.1093/jamia/ocw008

Figure 2:

Figure 2:

Lung cancer gene mutation-specific survival analysis at different time points; SNaPshot mutation panel testing began in July 2010. (A) survival curves as of March 2011, 3 months prior to the first significant finding; (B) in June 2012, EGFR mutation was statistically associated with superior survival, whereas KRAS mutation was statistically associated with inferior survival; (C) in December 2013, KRAS mutation is no longer significant; (D) at the most recent analysis (August 2015), EGFR mutation remains a significant predictor for survival. BRAF: v-raf murine sarcoma viral oncogene homolog B; EGFR: epidermal growth factor receptor; ERBB2: v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; KRAS: Kirsten rat sarcoma viral oncogene homolog; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha.